ArticleBMC medicine2021
Optimal SARS-CoV-2 vaccine allocation using real-time attack-rate estimates in Rhode Island and Massachusetts.
Article in BMC medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Probiotics supplements for the prevention of atopic dermatitis in children: an umbrella review.Frontiers in nutrition · 2025Pooled it
- Predictive models for health outcomes due to SARS-CoV-2, including the effect of vaccination: a systematic review.Systematic reviews · 2024Pooled it
- Optimal COVID-19 vaccine prioritization by age depends critically on inter-group contacts and vaccination rates.Royal Society open science · 2024Article
- Learning from the COVID-19 pandemic: A systematic review of mathematical vaccine prioritization models.Infectious Disease Modelling · 2024Review
- Article
- Incorporating social determinants of health into transmission modeling of COVID-19 vaccine in the US: a scoping review.Lancet regional health. Americas · 2024Article
- Vaccination for communicable endemic diseases: optimal allocation of initial and booster vaccine doses.Journal of mathematical biology · 2024Article
- Assessing the dynamics and impact of COVID-19 vaccination on disease spread: A data-driven approach.Infectious Disease Modelling · 2024Article
- Learning from the COVID-19 pandemic: a systematic review of mathematical vaccine prioritization models.medRxiv : the preprint server for health sciences · 2024Article
- Influenza vaccination allocation in tropical settings under constrained resources.medRxiv : the preprint server for health sciences · 2024Article
- Review
- Study of optimal vaccination strategies for early COVID-19 pandemic using an age-structured mathematical model: A case study of the USA.Mathematical biosciences and engineering : MBE · 2023Article
- Effect of vaccination patterns and vaccination rates on the spread and mortality of the COVID-19 pandemic.Health policy and technology · 2023Article
- Benefits of near-universal vaccination and treatment access to manage COVID-19 burden in the United States.medRxiv : the preprint server for health sciences · 2023Article
- Article
- Risk factors for severe Covid-19 breakthrough infections: an observational longitudinal study.BMC infectious diseases · 2022Observational
- Article
- Sequential allocation of vaccine to control an infectious disease.Mathematical biosciences · 2022Article
- COVID-19 pandemic over 2020 (withlockdowns) and 2021 (with vaccinations): similar effects for seasonality and environmental factors.Environmental research · 2022Article
- SARS-CoV-2 Attack Rate and Population Immunity in Southern New England, March 2020 to May 2021.JAMA network open · 2022Observational
Corrections and comments
- Update of
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundWhen three SARS-CoV-2 vaccines came to market in Europe and North America in the winter of 2020-2021, distribution networks were in a race against a major epidemiological wave of SARS-CoV-2 that began in autumn 2020. Rapid and optimized vaccine allocation was critical during this time. With 95% efficacy reported for two of the vaccines, near-term public health needs likely require that distribution is prioritized to the elderly, health care workers, teachers, essential workers, and individuals with comorbidities putting them at risk of severe clinical progression.
methodsWe evaluate various age-based vaccine distributions using a validated mathematical model based on current epidemic trends in Rhode Island and Massachusetts. We allow for varying waning efficacy of vaccine-induced immunity, as this has not yet been measured. We account for the fact that known COVID-positive cases may not have been included in the first round of vaccination. And, we account for age-specific immune patterns in both states at the time of the start of the vaccination program. Our analysis assumes that health systems during winter 2020-2021 had equal staffing and capacity to previous phases of the SARS-CoV-2 epidemic; we do not consider the effects of understaffed hospitals or unvaccinated medical staff.
resultsWe find that allocating a substantial proportion (>75%) of vaccine supply to individuals over the age of 70 is optimal in terms of reducing total cumulative deaths through mid-2021. This result is robust to different profiles of waning vaccine efficacy and several different assumptions on age mixing during and after lockdown periods. As we do not explicitly model other high-mortality groups, our results on vaccine allocation apply to all groups at high risk of mortality if infected. A median of 327 to 340 deaths can be avoided in Rhode Island (3444 to 3647 in Massachusetts) by optimizing vaccine allocation and vaccinating the elderly first. The vaccination campaigns are expected to save a median of 639 to 664 lives in Rhode Island and 6278 to 6618 lives in Massachusetts in the first half of 2021 when compared to a scenario with no vaccine. A policy of vaccinating only seronegative individuals avoids redundancy in vaccine use on individuals that may already be immune, and would result in 0.5% to 1% reductions in cumulative hospitalizations and deaths by mid-2021.
conclusionsAssuming high vaccination coverage (>28%) and no major changes in distancing, masking, gathering size, hygiene guidelines, and virus transmissibility between 1 January 2021 and 1 July 2021 a combination of vaccination and population immunity may lead to low or near-zero transmission levels by the second quarter of 2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.